Asset
Voclosporin
Aurinia Pharmaceuticals Inc Ordinary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (14)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00258713 | phase3 | completed | 2005-09-01 | 2006-07-01 | Aurinia Pharmaceuticals Inc. | A 36-Week Extension to Protocol ISA04-03 |
| NCT02949973 | phase2 | completed | 2015-06-01 | 2016-12-01 | Aurinia Pharmaceuticals Inc. | Aurinia Early Urinary Protein Reduction Predicts Response |
| NCT03597464 | phase3 | completed | 2019-09-29 | 2021-10-07 | Aurinia Pharmaceuticals Inc. | Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin |
| NCT03021499 | phase3 | completed | 2017-05-17 | 2019-09-24 | Aurinia Pharmaceuticals Inc. | Aurinia Renal Response in Active Lupus With Voclosporin |
| NCT03598036 | phase2 | terminated | 2018-06-21 | 2020-05-19 | Aurinia Pharmaceuticals Inc. | Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 213716 | NDA | AURINIA PHARMACEUTICALS INC |
Marketed products (1)
- LUPKYNIS